Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction

Circulation: Heart Failure

Volumn 4, Issue 1, 2011, Pages 44-52

  Westermann, Dirk ^a   Lindner, Diana ^a   Kasner, Mario ^a   Zietsch, Christine ^a   Savvatis, K ^a   Escher, F ^a   Schlippenbach, J Von ^a   Skurk, C ^a   Steendijk, Paul ^b   Riad, Alexander ^a   Poller, Wolfgang ^a   Schultheiss, Heinz Peter ^a   Tschöpe, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Collagen; Diastolic dysfunction; Inflammation; Remodeling

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN; DIURETIC AGENT; INTERSTITIAL COLLAGENASE; PROTEIN; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CARDITIS; CATHETER; CELL TRANSDIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FILLING; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY CELL; MYOFIBROBLAST; PRIORITY JOURNAL; STIMULATION; BIOPSY; CASE CONTROL STUDY; CELL CULTURE; DISEASE COURSE; DRUG EFFECT; FEMALE; FIBROSIS; HEART; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART STROKE VOLUME; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; BIOPSY; CASE-CONTROL STUDIES; CELLS, CULTURED; COLLAGEN; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBROBLASTS; FIBROSIS; HEART; HEART FAILURE; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; MYOCARDIUM; STROKE VOLUME; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR FUNCTION, LEFT;

EID: 79952260400     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.109.931451     Document Type: Article

References (52)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259. (Pubitemid 44079340)
2. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu P. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260-269. (Pubitemid 44088349)
3. Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M, Slama M, Massy Z. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J. 2008;29:339-347. (Pubitemid 351197754)
4. Gaasch WH, Delorey DE, Kueffer FJ, Zile R. Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure. Am J Cardiol. 2009; 104:1413-1415.
5. Ahmed A, Zile MR, Rich MW, Fleg JL, Adams KF Jr, Love TE, Young JB, Aronow WS, Kitzman DW, Gheorghiade M, Dell'Italia LJ. Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. Am J Cardiol. 2007;99:460-464. (Pubitemid 46215547)
6. Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss HP, Tschope C. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 2008;117:2057-2060.
7. Kasner M, Westermann D, Steendijk P, Gaub R, Wilkenshoff U, Weitmann K, Hoffmann W, Poller W, Schultheiss HP, Pauschinger, M. Tschope C. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation. 2007;116:637-647. (Pubitemid 47356348)
8. Zile MR, Baicu CF, Gaasch H. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953-1959.
9. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield M. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982-1990. (Pubitemid 46625948)
10. Phan TT, Abozguia K, Nallur Shivu G, Mahadevan G, Ahmed I, Williams L, Dwivedi G, Patel K, Steendijk P, Ashrafian H, Henning A, Frenneaux M. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol. 2009;54:402-409.
11. Wachter R, Schmidt-Schweda S, Westermann D, Post H, Edelmann F, Kasner M, Luers C, Steendijk P, Hasenfuss G, Tschope C, Pieske B. Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure. Eur Heart J. 2009;30: 3027-3036.
12. Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, Kass A. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation. 2006;114:2138-2147. (Pubitemid 44747894)
13. Tschope C, Westermann D. Heart failure with normal ejection fraction: pathophysiology, diagnosis, and treatment. Herz. 2009;34:89-96.
14. Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield M. Contractility and ventricular systolic stiffening in hypertensive heart disease: insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;54:410-418.
15. Tan YT, Wenzelburger F, Lee E, Heatlie G, Leyva F, Patel K, Frenneaux M, Sanderson E. The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol. 2009;54: 36-46.
16. Tschope C, Paulus WJ. Is echocardiographic evaluation of diastolic function useful in determining clinical care? Doppler echocardiography yields dubious estimates of left ventricular diastolic pressures. Circulation. 2009;120: 810-820; discussion 820.
17. Penicka M, Bartunek J, Trakalova H, Hrabakova H, Maruskova M, Karasek J, Kocka V. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: a pressure-volume loop analysis. J Am Coll Cardiol. 2010;55:1701-1710.
18. Deleted in proof.
19. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus J. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113:1966-1973.
20. Borbely A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, Paulus J. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111:774-781. (Pubitemid 40250638)
21. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbely A, van der Velden J, Stienen GJ, Laarman GJ, Niessen HW, Paulus J. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117:43-51. (Pubitemid 350291180)
22. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol. 2006;48:89-96. (Pubitemid 43929208)
23. Muller-Brunotte R, Kahan T, Lopez B, Edner M, Gonzalez A, Diez J, Malmqvist K. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens. 2007;25:1958-1966. (Pubitemid 47356638)
24. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen- Tervaert JW, Drexler H, Filippatos G, Felix SB, Gullestad L, Hilfiker- Kleiner D, Janssens S, Latini R, Neubauer G, Paulus WJ, Pieske B, Ponikowski P, Schroen B, Schultheiss HP, Tschope C, Van Bilsen M, Zannad F, McMurray J, Shah M. Inflammation as a therapeutic target in heart failure? a scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:119-129.
25. Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschope C. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes. 2007;56:641-646. (Pubitemid 46348458)
26. Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med. 2010;362:1248-1249.
27. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert L. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539-2550. (Pubitemid 47614269)
28. Tschope C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck PL, Pauschinger M, Poller WC, Kuhl U, Kandolf R, Schultheiss P. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation. 2005;111:879-886. (Pubitemid 40279889)
29. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Murphy NF, Conlon C, Patle A, Donnelly SC, McDonald K. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail. 2009;11:191-197.
30. Jaber WA, Maniu C, Krysiak J, Shapiro BP, Meyer DM, Linke WA, Redfield M. Titin isoforms, extracellular matrix, and global chamber remodeling in experimental dilated cardiomyopathy: functional implications and mechanistic insight. Circ Heart Fail. 2008;1:192-199.
31. Grutzner A, Garcia-Manyes S, Kotter S, Badilla CL, Fernandez JM, Linke A. Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence. Biophys J. 2009;97: 825-834.
32. Kruger M, Linke WA. Titin-based mechanical signalling in normal and failing myocardium. J Mol Cell Cardiol. 2009;46:490-498.
33. Laurent GJ. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol. 1987;252:C1-C9.
34. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997;96:4065-4082.
35. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure, part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105:1387-1393. (Pubitemid 34260433)
36. Querejeta R, Lopez B, Gonzalez A, Sanchez E, Larman M, Martinez Ubago JL, Diez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004;110: 1263-1268. (Pubitemid 39202343)
37. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, Kuhl U, Schultheiss P. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation. 1999;99: 2750-2756. (Pubitemid 29250020)
38. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530. (Pubitemid 34640901)
39. Westermann D, Savvatis K, Schultheiss HP, Tschope C. Immunomodulation and matrix metalloproteinases in viral myocarditis. J Mol Cell Cardiol. 2010;48:468-473.
40. Hall MC, Young DA, Waters JG, Rowan AD, Chantry A, Edwards DR, Clark M. The comparative role of activator protein 1 and Smad factors in the regulation of TIMP-1 and MMP-1 gene expression by transforming growth factor-β1. J Biol Chem. 2003;278:10304-10313. (Pubitemid 36800292)
41. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, Van de Werf F, Pinto YM, Janssens S. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation. 2005;112:1136-1144. (Pubitemid 41216120)
42. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007;87: 1285-1342. (Pubitemid 350041472)
43. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, Donnelly SC, McDonald K. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115:888-895. (Pubitemid 46294729)
44. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest. 2005; 115:599-609. (Pubitemid 40322234)
45. Mikko M, Fredriksson K, Wahlstrom J, Eriksson P, Grunewald J, Skold M. Human T cells stimulate fibroblast-mediated degradation of extracellular matrix in vitro. Clin Exp Immunol. 2008;151:317-325.
46. Abbate A, Bonanno E, Mauriello A, Bussani R, Biondi-Zoccai GG, Liuzzo G, Leone AM, Silvestri F, Dobrina A, Baldi F, Pandolfi F, Biasucci LM, Baldi A, Spagnoli LG, Crea F. Widespread myocardial inflammation and infarct-related artery patency. Circulation. 2004;110: 46-50. (Pubitemid 38880132)
47. Lisman KA, Stetson SJ, Koerner MM, Farmer JA, Torre-Amione G. The role of inflammation in the pathogenesis of heart failure. Curr Cardiol Rep. 2002;4:200-205.
48. Sciarretta S, Ferrucci A, Ciavarella GM, De Paolis P, Venturelli V, Tocci G, De Biase L, Rubattu S, Volpe M. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens. 2007;20:784-791. (Pubitemid 46951019)
49. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Schmidt A, Noutsias M, Song XY, Spillmann F, Riad A, Schultheiss HP, Tschope C. Tumor necrosis factor-β antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol. 2007;102:500-507. (Pubitemid 47578394)
50. Heymans S, Pauschinger M, De Palma A, Kallwellis-Opara A, Rutschow S, Swinnen M, Vanhoutte D, Gao F, Torpai R, Baker AH, Padalko E, Neyts J, Schultheiss HP, Van de Werf F, Carmeliet P, Pinto M. Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation. 2006; 114:565-573. (Pubitemid 44199646)
51. Towbin JA. Inflammatory cardiomyopathy: there is a specific matrix destruction in the course of the disease. Ernst Schering Research Foundation Workshop. Springer, Heidelberg, Germany. 2006:219-250.
52. Souders CA, Bowers SL, Baudino A. Cardiac fibroblast: the renaissance cell. Circ Res. 2009;105:1164-1176.